Dr. Stéphane Gobeil is a researcher at the Centre de recherche du CHU de Québec-Laval University and an associate professor in the Department of Molecular Medicine at the Faculty of Medicine at Laval University. He completed a postdoctoral training in the Program of Gene Function and Expression at the University of Massachusetts. During his training under the supervision of Dr. Michael R. Green, he developed a highly efficient genome-wide RNA interference screening strategy that was critical to the publication of several high-impact papers.

Dr. Gobeil’s laboratory uses cellular and molecular biology as well as functional genomics to identify and determine the function of genes involved in different inflammatory pathologies such as obesity and cancer. Another important interest of his lab is molecular pharmacology, which he uses to determine the action mechanism of new small molecules with anti-inflammatory and anti-tumor potential. These two research interests make this laboratory an environment conducive to the discovery and development of therapeutic targets and biomarkers.

CHUL
2705, boulevard Laurier
R-4720
Québec, Québec
Canada G1V 4G2
CHUL
2705, boulevard Laurier
R-4772
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 46441
+1 418-654-2298
Stephane.Gobeil@crchudequ...

Latest news

Data not available

32 entries « ‹ 1 of 4 › »

Defrene J, Berrazouane S, Esparza N, Page N, Cote MF, Gobeil S, Aoudjit F, Tessier PA

Deletion of S100a8 and S100a9 Enhances Skin Hyperplasia and Promotes the Th17 Response in Imiquimod-Induced Psoriasis.

Journal Article

J Immunol, 206 (3), pp. 505-514, 2021, ISSN: 0022-1767.

Abstract | Links:

Zarifi Khosroshahi M, Corin Chavez Alvarez A, Gagne-Boulet M, C-Gaudreault R, Gobeil S, Fortin S

Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugs.

Journal Article

J Pharm Pharmacol, 72 (2), pp. 249-258, 2020, ISSN: 0022-3573.

Abstract | Links:

Sheta R, Bachvarova M, Macdonald E, Gobeil S, Vanderhyden B, Bachvarov D

The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.

Journal Article

Int J Mol Sci, 20 (9), 2019.

Abstract | Links:

Perreault M, Maltais R, Kenmogne LC, Letourneau D, LeHoux JG, Gobeil S, Poirier D

Implication of STARD5 and cholesterol homeostasis disturbance in the endoplasmic reticulum stress-related response induced by pro-apoptotic aminosteroid RM-133.

Journal Article

Pharmacol Res, 128 , pp. 52-60, 2018, ISSN: 1043-6618.

Abstract | Links:

Clemenceau A, Boucherat O, Landry-Truchon K, Lamontagne M, Biardel S, Joubert P, Gobeil S, Secco B, Laplante M, Morissette M, Obeidat M, Timens W, Jeannotte L, Bosse Y

Lung cancer susceptibility genetic variants modulate HOXB2 expression in the lung.

Journal Article

Int J Dev Biol, 62 (11-12), pp. 857-864, 2018, ISSN: 0214-6282.

Abstract | Links:

Sheta R, Wang ZQ, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D

Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner.

Journal Article

Oncotarget, 8 (47), pp. 82506-82530, 2017, ISSN: 1949-2553.

Abstract | Links:

Fortin S, Charest-Morin X, Turcotte V, Lauvaux C, Lacroix J, Cote MF, Gobeil S, C-Gaudreault R

Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells.

Journal Article

J Med Chem, 60 (12), pp. 4963-4982, 2017, ISSN: 0022-2623.

Abstract | Links:

Faddaoui A, Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Gobeil S, Morin C, Ghani K, Bachvarov D

Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.

Journal Article

Cell Cycle, 16 (7), pp. 693-706, 2017, ISSN: 1538-4101.

Abstract | Links:

Secco B, Camire E, Briere MA, Caron A, Billong A, Gelinas Y, Lemay AM, Tharp KM, Lee PL, Gobeil S, Guimond JV, Patey N, Guertin DA, Stahl A, Haddad E, Marsolais D, Bosse Y, Birsoy K, Laplante M

Amplification of Adipogenic Commitment by VSTM2A.

Journal Article

Cell Rep, 18 (1), pp. 93-106, 2017.

Abstract | Links:

Fournier M, Bourriquen G, Lamaze FC, Cote MC, Fournier E, Joly-Beauparlant C, Caron V, Gobeil S, Droit A, Bilodeau S

FOXA and master transcription factors recruit Mediator and Cohesin to the core transcriptional regulatory circuitry of cancer cells.

Journal Article

Sci Rep, 6 , pp. 34962, 2016, ISSN: 2045-2322.

Abstract | Links:

32 entries « ‹ 1 of 4 › »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30
  • Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery